TrialCompass TCL
Back to results
Phase 1, Phase 2Not yet recruitingPriority 3 · Moderate priorityNCT07615283

Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This Phase 1, Phase 2 trial is testing Adebrelimab & SHR2554 for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Adebrelimab & SHR2554 (DRUG): ①Phase Ib : SHR2554 350 mg twice daily ; Adebrelimab 1200 mg, IV infusion for 1 cycle(21days) ②Phase II ：Adebrelimab RP2D (600 mg or 1200 mg ), IV infusion ,D1 Q3W ; SHR2554 : 350 mg，twice daily ; Up to 6 cycles. ③Maintenance therapy : SHR2554 350 mg，twice daily (28 days per cycle) ,not exceed 24 months.

Drugs / treatments
Adebrelimab & SHR2554
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma

NCT07615283

Phase: Phase 1, Phase 2 | Status: Not yet recruiting | Priority: Medium

Plain-language summary

This Phase 1, Phase 2 trial is testing Adebrelimab & SHR2554 for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

Adebrelimab & SHR2554 (DRUG): ①Phase Ib : SHR2554 350 mg twice daily ; Adebrelimab 1200 mg, IV infusion for 1 cycle(21days) ②Phase II ：Adebrelimab RP2D (600 mg or 1200 mg ), IV infusion ,D1 Q3W ; SHR2554 : 350 mg，twice daily ; Up to 6 cycles. ③Maintenance therapy : SHR2554 350 mg，twice daily (28 days per cycle) ,not exceed 24 months.

Drugs / treatments: Adebrelimab & SHR2554

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 40 patients

Primary endpoint: Phase Ib: Dose limited toxicities (DLTs); Phase Ib: Recommended Phase II Dose (RP2D); Objective response rate (ORR)

Ages: 18 Years to —

Start date: 2026-05-29 | Est. completion: 2030-10-29

Locations

0 US sites · 1 total

Contact

Huiqiang Huang, M.D | huanghq@sysucc.org.cn | 020-87343349

Sponsor: Sun Yat-sen University (OTHER)

Tags

ENKTL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07615283

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.